Novel SCS Microinjector® shows a demonstrated ability for precise delivery into the suprachoroidal space SCS injection procedure commercially accepted by retinal physicians following launch of XIPERE® • Thousands of SCS injections performed Safety profile comparable to intravitreal injections1 • No Serious Adverse Events (SAEs) involving lens injury, suprachoroidal hemorrhage, or endophthalmitis have been observed 6 clinical trials ongoing including partner programs Sources: Clearside data on file | 1Kurup, ...